Dr. Paul M. Barr
Claim this profileUniversity of Rochester
Expert in Breast Cancer
Expert in Lymphoma
85 reported clinical trials
166 drugs studied
About Paul M. Barr
Education:
- Earned an MD from Northeast Ohio Medical University in 2000.
Experience:
- Completed internship, residency, and chief residency at Case Western Reserve University.
- Fellowship in Hematology and Oncology at Case Western.
- Holds subspecialty certification in Hematology and Oncology.
- Serves as an Associate Professor of Medicine at the University of Rochester.
- Director of the Clinical Trials Office for the Wilmot Cancer Institute.
Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage I
Stage II
2Lymphoma
Global LeaderStage IV
CCND1 positive
t(11;14) positive
Affiliated Hospitals
Clinical Trials Paul M. Barr is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Multiple Targeted Therapies
for Meningioma
This trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Recruiting1 award Phase 210 criteria
More about Paul M. Barr
Clinical Trial Related6 years of experience running clinical trials · Led 85 trials as a Principal Investigator · 41 Active Clinical TrialsTreatments Paul M. Barr has experience with
- Nivolumab
- Cisplatin
- Pembrolizumab
- Carboplatin
- Cytarabine
- Cyclophosphamide
Breakdown of trials Paul M. Barr has run
Breast Cancer
Lymphoma
Adult T-Cell Leukemia/Lymphoma
Lung Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Paul M. Barr specialize in?
Is Paul M. Barr currently recruiting for clinical trials?
Are there any treatments that Paul M. Barr has studied deeply?
What is the best way to schedule an appointment with Paul M. Barr?
What is the office address of Paul M. Barr?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.